Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Home›Companies›Argenx
Argenx logo

Argenx

Reaching Patients Through Immunology Innovation
Ghent, Belgium Biotech 1,100 employees Founded 2008 ARGX argenx.com ↗
3 Products & services
2 Licensed medicines
40 Clinical trials
1,100 Employees

About Argenx

Argenx is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for autoimmune diseases and cancer.

Sector
Biotech
Headquarters
Ghent, Belgium
Founded
2008
Employees
1,100

Leadership Team

Leadership as listed on argenx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Karen Massey

Chief Executive Officer, Executive Director of the Board of Directors
Source: argenx.com

Karl Gubitz

Chief Financial Officer
Source: argenx.com

Peter Ulrichts

Chief Scientific Officer
Source: argenx.com

Luc Truyen

Chief Medical Officer
Source: argenx.com

Malini Moorthy

General Counsel
Source: argenx.com

Sandrine Piret-Gerard

Chief Commercialization Officer
Source: argenx.com

Products & Services

Products and services as listed on argenx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

All Immunology Pipeline - immunology
Immunology

VYVGART (efgartigimod)

Therapy designed to block FcRn, marketed for generalized myasthenia gravis.

Source: argenx.com
Immunology

VYVGART Hytrulo

Efgartigimod formulation marketed for gMG and CIDP.

Source: argenx.com
Pipeline - immunology

Empasiprubart

Investigational therapy for severe IgM-driven autoimmune diseases.

Source: argenx.com

Pipeline & Regulatory Record

What public registers list for Argenx: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 20 Nov 2026.

40Trials as lead sponsor
22Recruiting now
4With a site in Ireland
0FDA device clearances

Clinical trials 40 in our ClinicalTrials.gov registers · 6 in the EU register

StudyPhaseStatus
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847 · site in Ireland · Primary Sjogrens Disease
Phase 3Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925 · site in Ireland · Primary Immune Thrombocytopenia
Phase 3Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441 · site in Ireland · Myositis, Active Idiopathic Inflammatory Myopathy
Phase 3By invitation
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499 · site in Ireland · Primary Immune Thrombocytopenia (ITP)
Phase 3Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190 · Multifocal Motor Neuropathy (MMN), MMN
Phase 3Active, closed
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155 · Systemic Sclerosis (SSc)
Phase 2Active, closed
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742 · Congenital Myasthenic Syndrome, CMS
Phase 1Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279 · Myasthenia Gravis, Ocular
Phase 3Active, closed
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
NCT06503731 · Antibody-mediated Rejection
Phase 2Active, closed
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954 · Dermatomyositis, Myositis
Phase 2Active, closed

Showing 10 of 40, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 6 compounds

EU trials register (CTIS) 6 authorised or ongoing

NICE technology appraisals 1 of its medicines · 1 current

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Argenx): founded 2008, headquarters Ghent, website argenx.com. Wikidata Q63152908 · Wikipedia. From Wikidata (CC0), matched by the group's Legal Entity Identifier.

How this is matched: register records are linked to this page by the organisation name they carry, here argenx; Argenx. Spot a wrong match? Tell us.

Financials & Irish Entities

From the annual reports argenx SE files with the US Securities and Exchange Commission (20-F, IFRS), in USD as reported. Latest financial year: to Dec 2025.

$4.2bnRevenue
$1.4bnR&D expense
32.9%R&D as % of revenue
$1.3bnNet income (31.1% margin)
Revenue and R&D expense, USD bn$0.0bn$1.0bn$2.0bn$3.0bn$4.0bn$5.0bnDec 2021Dec 2022Dec 2023Dec 2024Dec 2025Dec 2021: $0.5bn (Revenue)Dec 2022: $0.4bn (Revenue)Dec 2023: $1.2bn (Revenue)Dec 2024: $2.2bn (Revenue)Dec 2025: $4.2bn (Revenue)RevenueDec 2021: $0.6bn (R&D expense)Dec 2022: $0.7bn (R&D expense)Dec 2023: $0.9bn (R&D expense)Dec 2024: $1.0bn (R&D expense)Dec 2025: $1.4bn (R&D expense)R&D expense
RevenueR&D expense
Year toRevenueR&DR&D %Net incomeFiling
Dec 2025$4.15bn$1.36bn32.9%$1.29bn20-F 2026
Dec 2024$2.19bn$983m45.0%$833m20-F 2026
Dec 2023$1.19bn$859m72.2%−$295m20-F 2026
Dec 2022$401m$663m165.5%−$710m20-F 2025
Dec 2021$497m$581m116.7%−$408m20-F 2024

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

In the News

No coverage yet — our newsroom tracks Argenx continuously.

Research Publications

EUROPE PMC · LIVE
Searching Europe PMC for affiliated publications...

FDA Recalls (US)

OPENFDA · LIVE
Checking openFDA drug-recall records...